Beyond Air to announce fiscal year 2026 results on June 26
Beyond Air will announce its fiscal Q4 and full-year 2026 financial results on June 26, 2026, followed by a conference call and webcast at 8:00 am ET. The company specializes in nitric oxide-based therapies for respiratory and neurological conditions.
*this image is generated using AI for illustrative purposes only.
Beyond Air will report its financial results for the fiscal fourth quarter and full year ended March 31, 2026, on Friday, June 26, 2026. The announcement will provide insights into the commercial-stage medical device and biopharmaceutical company's performance for the period. Management is scheduled to host a conference call and webcast at 8:00 am Eastern Time (ET) the same day to discuss the results.
Conference Call Details
Investors and interested parties can access the live conference call using the following details:
| Category | Details |
|---|---|
| Domestic | 1-877-407-0784 |
| International | 1-201-689-8560 |
| Conference ID | 13761239 |
A webcast of the live call will be available on the Events section of Beyond Air's website. An online replay will be accessible one hour after the call concludes.
About Beyond Air
Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on harnessing nitric oxide (NO) to treat respiratory illnesses, neurological disorders, and solid tumors. The company has received FDA approval and CE Mark for its LungFit PH system, designed to treat term and near-term neonates with hypoxic respiratory failure.
What are the expected revenue growth drivers for Beyond Air in the fiscal year ending March 31, 2027?
How might the commercialization of the LungFit PH system impact Beyond Air's market share in the neonatal respiratory care segment?
What regulatory milestones could Beyond Air achieve in the next 12 months for its nitric oxide-based treatments in neurological disorders or solid tumors?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
